IP Library › Granted Patent US 10,512,688
Granted Patent B2
US 10,512,688 · App. 15/325,364 · Granted Dec 24, 2019

Antibodies binding AXL

Inventors: Esther Breij (Utrecht, NL); David Satijn (Utrecht, NL); Edward Norbert Van Den Brink (Halfweg, NL); Dennis Verzijl (Amstelveen, NL); Rob N. De Jong (Utrecht, NL); Paul Parren (Utrecht, NL); Riemke Van Dijkhuizen Radersma (Zeist, NL)
Assignee: GENMAB A/S
A61K39/39558A61K47/6801A61K47/6855A61K47/6857A61K47/6869C07K16/2863C07K16/3061A61K2039/505A61K2121/00C07K2317/33C07K2317/34C07K2317/56C07K2317/732C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,512,688
App. No.
15/325,364
Granted
Dec 24, 2019
Kind
B2
Abstract

The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

Claims (14)

1. A method of diagnosing a cancer characterized by AXL expression, comprising administering to a subject at risk of developing said cancer

an antibody which binds to AXL and detecting the amount of bound antibody,

wherein the antibody comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 36, 37, and 38, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NO: 39, GAS, and SEQ ID NO: 40, respectively,

wherein accumulation of AXL-expressing cells is indicative of the presence of the cancer.

2. The method of claim 1 , wherein said antibody comprises a VH region comprising SEQ ID NO: 1 and a VL region comprising SEQ ID NO: 2.

3. The method of claim 1 , wherein said antibody binds to an epitope within positions L121 to Q129 of human AXL (SEQ ID NO: 130).

4. The method of claim 1 , wherein said antibody comprises a heavy chain of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

5. The method of claim 1 , wherein the antibody is a full-length monoclonal antibody.

6. The method of claim 1 , wherein the antibody is an effector-function-deficient antibody, a stabilized IgG4 antibody, or a monovalent antibody.

7. The method of claim 1 , wherein the antibody is a single-chain antibody.

8. A method of diagnosing a cancer characterized by AXL expression, comprising administering a pharmaceutical composition to a subject at risk of developing said cancer comprising

an antibody which binds to AXL, and detecting the amount of bound antibody,

wherein the antibody comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 36, 37, and 38, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NO: 39, GAS, and SEQ ID NO: 40, respectively,

wherein accumulation of AXL-expressing cells, is indicative of the presence of the cancer.

Assignments (3)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB HOLDING B.V.; GENMAB A/S; GENMAB B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2018
From: BREIJ, ESTHER; SATIJN, DAVID; VAN DEN BRINK, EDWARD; VERZIJL, DENNIS; DE JONG, ROB N.; PARREN, PAUL; RADERSMA, RIEMKE VAN DIJKHUIZEN
To: GENMAB A/S
Reel/Frame 048552/0528 →
Cited By (1)
US 12,589,150